CN108823258B - Oxidation method using whole cells as catalyst - Google Patents
Oxidation method using whole cells as catalyst Download PDFInfo
- Publication number
- CN108823258B CN108823258B CN201810755903.9A CN201810755903A CN108823258B CN 108823258 B CN108823258 B CN 108823258B CN 201810755903 A CN201810755903 A CN 201810755903A CN 108823258 B CN108823258 B CN 108823258B
- Authority
- CN
- China
- Prior art keywords
- nad
- cells
- bridged
- flavin
- oxidation
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Active
Links
- 238000007254 oxidation reaction Methods 0.000 title claims abstract description 38
- 238000000034 method Methods 0.000 title claims abstract description 33
- 239000003054 catalyst Substances 0.000 title claims abstract description 24
- 230000003647 oxidation Effects 0.000 title claims abstract description 22
- AUNGANRZJHBGPY-SCRDCRAPSA-N Riboflavin Chemical compound OC[C@@H](O)[C@@H](O)[C@@H](O)CN1C=2C=C(C)C(C)=CC=2N=C2C1=NC(=O)NC2=O AUNGANRZJHBGPY-SCRDCRAPSA-N 0.000 claims abstract description 43
- 230000003834 intracellular effect Effects 0.000 claims abstract description 29
- 108090000854 Oxidoreductases Proteins 0.000 claims abstract description 17
- 102000004316 Oxidoreductases Human genes 0.000 claims abstract description 17
- 230000001419 dependent effect Effects 0.000 claims abstract description 15
- 102000004190 Enzymes Human genes 0.000 claims abstract description 11
- 108090000790 Enzymes Proteins 0.000 claims abstract description 11
- 230000001172 regenerating effect Effects 0.000 claims abstract description 4
- 241000588724 Escherichia coli Species 0.000 claims description 47
- 230000003197 catalytic effect Effects 0.000 claims description 22
- 108020000290 Mannitol dehydrogenase Proteins 0.000 claims description 21
- 239000000758 substrate Substances 0.000 claims description 20
- 239000000243 solution Substances 0.000 claims description 18
- 244000063299 Bacillus subtilis Species 0.000 claims description 13
- 235000014469 Bacillus subtilis Nutrition 0.000 claims description 13
- VEXZGXHMUGYJMC-UHFFFAOYSA-M Chloride anion Chemical compound [Cl-] VEXZGXHMUGYJMC-UHFFFAOYSA-M 0.000 claims description 11
- 230000008569 process Effects 0.000 claims description 11
- 108090000623 proteins and genes Proteins 0.000 claims description 9
- 101000892220 Geobacillus thermodenitrificans (strain NG80-2) Long-chain-alcohol dehydrogenase 1 Proteins 0.000 claims description 8
- 150000002211 flavins Chemical class 0.000 claims description 8
- 240000004808 Saccharomyces cerevisiae Species 0.000 claims description 7
- 229910052739 hydrogen Inorganic materials 0.000 claims description 7
- 239000001257 hydrogen Substances 0.000 claims description 7
- 239000007788 liquid Substances 0.000 claims description 7
- 241000193401 Clostridium acetobutylicum Species 0.000 claims description 6
- -1 halide ion Chemical class 0.000 claims description 6
- 239000002244 precipitate Substances 0.000 claims description 6
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 claims description 5
- 241000228245 Aspergillus niger Species 0.000 claims description 4
- 241000186226 Corynebacterium glutamicum Species 0.000 claims description 4
- ZSLZBFCDCINBPY-ZSJPKINUSA-N acetyl-CoA Chemical compound O[C@@H]1[C@H](OP(O)(O)=O)[C@@H](COP(O)(=O)OP(O)(=O)OCC(C)(C)[C@@H](O)C(=O)NCCC(=O)NCCSC(=O)C)O[C@H]1N1C2=NC=NC(N)=C2N=C1 ZSLZBFCDCINBPY-ZSJPKINUSA-N 0.000 claims description 4
- 238000000926 separation method Methods 0.000 claims description 4
- 230000005526 G1 to G0 transition Effects 0.000 claims description 3
- 241000235070 Saccharomyces Species 0.000 claims description 3
- 241000187747 Streptomyces Species 0.000 claims description 3
- 239000007853 buffer solution Substances 0.000 claims description 3
- 239000012930 cell culture fluid Substances 0.000 claims description 3
- 125000005843 halogen group Chemical group 0.000 claims description 3
- 125000002023 trifluoromethyl group Chemical group FC(F)(F)* 0.000 claims description 3
- 125000006527 (C1-C5) alkyl group Chemical group 0.000 claims description 2
- 108010021809 Alcohol dehydrogenase Proteins 0.000 claims description 2
- 102000007698 Alcohol dehydrogenase Human genes 0.000 claims description 2
- 101710088194 Dehydrogenase Proteins 0.000 claims description 2
- 125000001797 benzyl group Chemical group [H]C1=C([H])C([H])=C(C([H])=C1[H])C([H])([H])* 0.000 claims description 2
- 238000004113 cell culture Methods 0.000 claims description 2
- 230000001413 cellular effect Effects 0.000 claims description 2
- 230000007423 decrease Effects 0.000 claims description 2
- 125000000956 methoxy group Chemical group [H]C([H])([H])O* 0.000 claims description 2
- 125000000449 nitro group Chemical group [O-][N+](*)=O 0.000 claims description 2
- YPJKMVATUPSWOH-UHFFFAOYSA-N nitrooxidanyl Chemical compound [O][N+]([O-])=O YPJKMVATUPSWOH-UHFFFAOYSA-N 0.000 claims description 2
- 125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 claims description 2
- 125000002924 primary amino group Chemical group [H]N([H])* 0.000 claims description 2
- 230000001502 supplementing effect Effects 0.000 claims description 2
- 125000004435 hydrogen atom Chemical class [H]* 0.000 claims 2
- 210000004027 cell Anatomy 0.000 abstract description 49
- 230000008929 regeneration Effects 0.000 abstract description 12
- 238000011069 regeneration method Methods 0.000 abstract description 12
- DFPAKSUCGFBDDF-UHFFFAOYSA-N Nicotinamide Chemical compound NC(=O)C1=CC=CN=C1 DFPAKSUCGFBDDF-UHFFFAOYSA-N 0.000 abstract description 10
- 230000001276 controlling effect Effects 0.000 abstract description 6
- 108010052285 Membrane Proteins Proteins 0.000 abstract description 5
- 229960003966 nicotinamide Drugs 0.000 abstract description 5
- 235000005152 nicotinamide Nutrition 0.000 abstract description 5
- 239000011570 nicotinamide Substances 0.000 abstract description 5
- 230000001105 regulatory effect Effects 0.000 abstract description 4
- 102000018697 Membrane Proteins Human genes 0.000 abstract description 3
- 210000000170 cell membrane Anatomy 0.000 abstract description 3
- 230000035699 permeability Effects 0.000 abstract description 3
- 230000001988 toxicity Effects 0.000 abstract description 3
- 231100000419 toxicity Toxicity 0.000 abstract description 3
- BAWFJGJZGIEFAR-NNYOXOHSSA-O NAD(+) Chemical compound NC(=O)C1=CC=C[N+]([C@H]2[C@@H]([C@H](O)[C@@H](COP(O)(=O)OP(O)(=O)OC[C@@H]3[C@H]([C@@H](O)[C@@H](O3)N3C4=NC=NC(N)=C4N=C3)O)O2)O)=C1 BAWFJGJZGIEFAR-NNYOXOHSSA-O 0.000 description 49
- 238000006243 chemical reaction Methods 0.000 description 39
- 239000005977 Ethylene Substances 0.000 description 25
- WQZGKKKJIJFFOK-QTVWNMPRSA-N D-mannopyranose Chemical compound OC[C@H]1OC(O)[C@@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-QTVWNMPRSA-N 0.000 description 21
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 18
- FBPFZTCFMRRESA-KVTDHHQDSA-N D-Mannitol Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-KVTDHHQDSA-N 0.000 description 14
- 229930195725 Mannitol Natural products 0.000 description 14
- 239000000594 mannitol Substances 0.000 description 14
- 235000010355 mannitol Nutrition 0.000 description 14
- 108020004705 Codon Proteins 0.000 description 13
- PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 description 12
- 150000003841 chloride salts Chemical class 0.000 description 10
- 239000013612 plasmid Substances 0.000 description 9
- 239000013598 vector Substances 0.000 description 8
- 101710117857 NADP-dependent mannitol dehydrogenase Proteins 0.000 description 7
- 101710187165 Probable NADP-dependent mannitol dehydrogenase Proteins 0.000 description 7
- 239000002609 medium Substances 0.000 description 7
- 238000005457 optimization Methods 0.000 description 7
- ROWKJAVDOGWPAT-UHFFFAOYSA-N Acetoin Chemical compound CC(O)C(C)=O ROWKJAVDOGWPAT-UHFFFAOYSA-N 0.000 description 6
- LRHPLDYGYMQRHN-UHFFFAOYSA-N N-Butanol Chemical compound CCCCO LRHPLDYGYMQRHN-UHFFFAOYSA-N 0.000 description 6
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 6
- XJLXINKUBYWONI-DQQFMEOOSA-N [[(2r,3r,4r,5r)-5-(6-aminopurin-9-yl)-3-hydroxy-4-phosphonooxyoxolan-2-yl]methoxy-hydroxyphosphoryl] [(2s,3r,4s,5s)-5-(3-carbamoylpyridin-1-ium-1-yl)-3,4-dihydroxyoxolan-2-yl]methyl phosphate Chemical compound NC(=O)C1=CC=C[N+]([C@@H]2[C@H]([C@@H](O)[C@H](COP([O-])(=O)OP(O)(=O)OC[C@@H]3[C@H]([C@@H](OP(O)(O)=O)[C@@H](O3)N3C4=NC=NC(N)=C4N=C3)O)O2)O)=C1 XJLXINKUBYWONI-DQQFMEOOSA-N 0.000 description 6
- 230000014509 gene expression Effects 0.000 description 6
- 238000000338 in vitro Methods 0.000 description 6
- 229930027945 nicotinamide-adenine dinucleotide Natural products 0.000 description 6
- 239000008057 potassium phosphate buffer Substances 0.000 description 6
- 239000000047 product Substances 0.000 description 6
- 239000012295 chemical reaction liquid Substances 0.000 description 5
- 230000000052 comparative effect Effects 0.000 description 5
- 238000010276 construction Methods 0.000 description 5
- 150000002431 hydrogen Chemical class 0.000 description 5
- 101000886933 Geobacillus stearothermophilus Glycerol dehydrogenase Proteins 0.000 description 4
- RXKJFZQQPQGTFL-UHFFFAOYSA-N dihydroxyacetone Chemical compound OCC(=O)CO RXKJFZQQPQGTFL-UHFFFAOYSA-N 0.000 description 4
- 238000000855 fermentation Methods 0.000 description 4
- 230000004151 fermentation Effects 0.000 description 4
- 239000001963 growth medium Substances 0.000 description 4
- 238000002360 preparation method Methods 0.000 description 4
- 238000000746 purification Methods 0.000 description 4
- 230000033228 biological regulation Effects 0.000 description 3
- 239000000872 buffer Substances 0.000 description 3
- 238000006911 enzymatic reaction Methods 0.000 description 3
- GFAZHVHNLUBROE-UHFFFAOYSA-N hydroxymethyl propionaldehyde Natural products CCC(=O)CO GFAZHVHNLUBROE-UHFFFAOYSA-N 0.000 description 3
- 238000010369 molecular cloning Methods 0.000 description 3
- BOPGDPNILDQYTO-NNYOXOHSSA-N nicotinamide-adenine dinucleotide Chemical compound C1=CCC(C(=O)N)=CN1[C@H]1[C@H](O)[C@H](O)[C@@H](COP(O)(=O)OP(O)(=O)OC[C@@H]2[C@H]([C@@H](O)[C@@H](O2)N2C3=NC=NC(N)=C3N=C2)O)O1 BOPGDPNILDQYTO-NNYOXOHSSA-N 0.000 description 3
- 230000002018 overexpression Effects 0.000 description 3
- 238000006479 redox reaction Methods 0.000 description 3
- 239000011780 sodium chloride Substances 0.000 description 3
- YBJHBAHKTGYVGT-ZKWXMUAHSA-N (+)-Biotin Chemical compound N1C(=O)N[C@@H]2[C@H](CCCCC(=O)O)SC[C@@H]21 YBJHBAHKTGYVGT-ZKWXMUAHSA-N 0.000 description 2
- QKNYBSVHEMOAJP-UHFFFAOYSA-N 2-amino-2-(hydroxymethyl)propane-1,3-diol;hydron;chloride Chemical compound Cl.OCC(N)(CO)CO QKNYBSVHEMOAJP-UHFFFAOYSA-N 0.000 description 2
- ALYNCZNDIQEVRV-UHFFFAOYSA-N 4-aminobenzoic acid Chemical compound NC1=CC=C(C(O)=O)C=C1 ALYNCZNDIQEVRV-UHFFFAOYSA-N 0.000 description 2
- 241000276408 Bacillus subtilis subsp. subtilis str. 168 Species 0.000 description 2
- 108700010070 Codon Usage Proteins 0.000 description 2
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 2
- 101150047731 MTDH gene Proteins 0.000 description 2
- 239000001888 Peptone Substances 0.000 description 2
- 108010080698 Peptones Proteins 0.000 description 2
- 238000004458 analytical method Methods 0.000 description 2
- 230000015572 biosynthetic process Effects 0.000 description 2
- 238000005859 coupling reaction Methods 0.000 description 2
- OPTASPLRGRRNAP-UHFFFAOYSA-N cytosine Chemical compound NC=1C=CNC(=O)N=1 OPTASPLRGRRNAP-UHFFFAOYSA-N 0.000 description 2
- 229940120503 dihydroxyacetone Drugs 0.000 description 2
- 239000008103 glucose Substances 0.000 description 2
- 108010017391 lysylvaline Proteins 0.000 description 2
- 230000001404 mediated effect Effects 0.000 description 2
- 235000019319 peptone Nutrition 0.000 description 2
- LWIHDJKSTIGBAC-UHFFFAOYSA-K potassium phosphate Substances [K+].[K+].[K+].[O-]P([O-])([O-])=O LWIHDJKSTIGBAC-UHFFFAOYSA-K 0.000 description 2
- HTSGKJQDMSTCGS-UHFFFAOYSA-N 1,4-bis(4-chlorophenyl)-2-(4-methylphenyl)sulfonylbutane-1,4-dione Chemical compound C1=CC(C)=CC=C1S(=O)(=O)C(C(=O)C=1C=CC(Cl)=CC=1)CC(=O)C1=CC=C(Cl)C=C1 HTSGKJQDMSTCGS-UHFFFAOYSA-N 0.000 description 1
- GORKKVHIBWAQHM-GCJQMDKQSA-N Ala-Asn-Thr Chemical compound [H]N[C@@H](C)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H]([C@@H](C)O)C(O)=O GORKKVHIBWAQHM-GCJQMDKQSA-N 0.000 description 1
- BUDNAJYVCUHLSV-ZLUOBGJFSA-N Ala-Asp-Ser Chemical compound C[C@H](N)C(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H](CO)C(O)=O BUDNAJYVCUHLSV-ZLUOBGJFSA-N 0.000 description 1
- QUIGLPSHIFPEOV-CIUDSAMLSA-N Ala-Lys-Ala Chemical compound [H]N[C@@H](C)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](C)C(O)=O QUIGLPSHIFPEOV-CIUDSAMLSA-N 0.000 description 1
- NINQYGGNRIBFSC-CIUDSAMLSA-N Ala-Lys-Ser Chemical compound NCCCC[C@H](NC(=O)[C@@H](N)C)C(=O)N[C@@H](CO)C(O)=O NINQYGGNRIBFSC-CIUDSAMLSA-N 0.000 description 1
- ADSGHMXEAZJJNF-DCAQKATOSA-N Ala-Pro-Leu Chemical compound CC(C)C[C@@H](C(O)=O)NC(=O)[C@@H]1CCCN1C(=O)[C@H](C)N ADSGHMXEAZJJNF-DCAQKATOSA-N 0.000 description 1
- WNHNMKOFKCHKKD-BFHQHQDPSA-N Ala-Thr-Gly Chemical compound [H]N[C@@H](C)C(=O)N[C@@H]([C@@H](C)O)C(=O)NCC(O)=O WNHNMKOFKCHKKD-BFHQHQDPSA-N 0.000 description 1
- USFZMSVCRYTOJT-UHFFFAOYSA-N Ammonium acetate Chemical compound N.CC(O)=O USFZMSVCRYTOJT-UHFFFAOYSA-N 0.000 description 1
- 239000005695 Ammonium acetate Substances 0.000 description 1
- YSUVMPICYVWRBX-VEVYYDQMSA-N Arg-Asp-Thr Chemical compound [H]N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H]([C@@H](C)O)C(O)=O YSUVMPICYVWRBX-VEVYYDQMSA-N 0.000 description 1
- UZGFHWIJWPUPOH-IHRRRGAJSA-N Arg-Leu-Lys Chemical compound CC(C)C[C@@H](C(=O)N[C@@H](CCCCN)C(=O)O)NC(=O)[C@H](CCCN=C(N)N)N UZGFHWIJWPUPOH-IHRRRGAJSA-N 0.000 description 1
- AUIJUTGLPVHIRT-FXQIFTODSA-N Arg-Ser-Cys Chemical compound C(C[C@@H](C(=O)N[C@@H](CO)C(=O)N[C@@H](CS)C(=O)O)N)CN=C(N)N AUIJUTGLPVHIRT-FXQIFTODSA-N 0.000 description 1
- FRBAHXABMQXSJQ-FXQIFTODSA-N Arg-Ser-Ser Chemical compound [H]N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CO)C(=O)N[C@@H](CO)C(O)=O FRBAHXABMQXSJQ-FXQIFTODSA-N 0.000 description 1
- JRVABKHPWDRUJF-UBHSHLNASA-N Asn-Asn-Trp Chemical compound C1=CC=C2C(=C1)C(=CN2)C[C@@H](C(=O)O)NC(=O)[C@H](CC(=O)N)NC(=O)[C@H](CC(=O)N)N JRVABKHPWDRUJF-UBHSHLNASA-N 0.000 description 1
- SGAUXNZEFIEAAI-GARJFASQSA-N Asn-His-Pro Chemical compound C1C[C@@H](N(C1)C(=O)[C@H](CC2=CN=CN2)NC(=O)[C@H](CC(=O)N)N)C(=O)O SGAUXNZEFIEAAI-GARJFASQSA-N 0.000 description 1
- VWADICJNCPFKJS-ZLUOBGJFSA-N Asn-Ser-Asp Chemical compound [H]N[C@@H](CC(N)=O)C(=O)N[C@@H](CO)C(=O)N[C@@H](CC(O)=O)C(O)=O VWADICJNCPFKJS-ZLUOBGJFSA-N 0.000 description 1
- SVABRQFIHCSNCI-FOHZUACHSA-N Asp-Gly-Thr Chemical compound [H]N[C@@H](CC(O)=O)C(=O)NCC(=O)N[C@@H]([C@@H](C)O)C(O)=O SVABRQFIHCSNCI-FOHZUACHSA-N 0.000 description 1
- WYOSXGYAKZQPGF-SRVKXCTJSA-N Asp-His-His Chemical compound C1=C(NC=N1)C[C@@H](C(=O)N[C@@H](CC2=CN=CN2)C(=O)O)NC(=O)[C@H](CC(=O)O)N WYOSXGYAKZQPGF-SRVKXCTJSA-N 0.000 description 1
- NZWDWXSWUQCNMG-GARJFASQSA-N Asp-Lys-Pro Chemical compound C1C[C@@H](N(C1)C(=O)[C@H](CCCCN)NC(=O)[C@H](CC(=O)O)N)C(=O)O NZWDWXSWUQCNMG-GARJFASQSA-N 0.000 description 1
- KGHLGJAXYSVNJP-WHFBIAKZSA-N Asp-Ser-Gly Chemical compound OC(=O)C[C@H](N)C(=O)N[C@@H](CO)C(=O)NCC(O)=O KGHLGJAXYSVNJP-WHFBIAKZSA-N 0.000 description 1
- 241000193830 Bacillus <bacterium> Species 0.000 description 1
- 241000193403 Clostridium Species 0.000 description 1
- FKLJPTJMIBLJAV-UHFFFAOYSA-N Compound IV Chemical compound O1N=C(C)C=C1CCCCCCCOC1=CC=C(C=2OCCN=2)C=C1 FKLJPTJMIBLJAV-UHFFFAOYSA-N 0.000 description 1
- UWXFFVQPAMBETM-ZLUOBGJFSA-N Cys-Asp-Asn Chemical compound [H]N[C@@H](CS)C(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H](CC(N)=O)C(O)=O UWXFFVQPAMBETM-ZLUOBGJFSA-N 0.000 description 1
- RWGDABDXVXRLLH-ACZMJKKPSA-N Cys-Glu-Asn Chemical compound C(CC(=O)O)[C@@H](C(=O)N[C@@H](CC(=O)N)C(=O)O)NC(=O)[C@H](CS)N RWGDABDXVXRLLH-ACZMJKKPSA-N 0.000 description 1
- WAJDEKCJRKGRPG-CIUDSAMLSA-N Cys-His-Ser Chemical compound C1=C(NC=N1)C[C@@H](C(=O)N[C@@H](CO)C(=O)O)NC(=O)[C@H](CS)N WAJDEKCJRKGRPG-CIUDSAMLSA-N 0.000 description 1
- OHLLDUNVMPPUMD-DCAQKATOSA-N Cys-Leu-Val Chemical compound CC(C)C[C@@H](C(=O)N[C@@H](C(C)C)C(=O)O)NC(=O)[C@H](CS)N OHLLDUNVMPPUMD-DCAQKATOSA-N 0.000 description 1
- ZQPOVSJFBBETHQ-CIUDSAMLSA-N Gln-Glu-Gln Chemical compound [H]N[C@@H](CCC(N)=O)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CCC(N)=O)C(O)=O ZQPOVSJFBBETHQ-CIUDSAMLSA-N 0.000 description 1
- ITYRYNUZHPNCIK-GUBZILKMSA-N Glu-Ala-Leu Chemical compound [H]N[C@@H](CCC(O)=O)C(=O)N[C@@H](C)C(=O)N[C@@H](CC(C)C)C(O)=O ITYRYNUZHPNCIK-GUBZILKMSA-N 0.000 description 1
- IQACOVZVOMVILH-FXQIFTODSA-N Glu-Glu-Ser Chemical compound [H]N[C@@H](CCC(O)=O)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CO)C(O)=O IQACOVZVOMVILH-FXQIFTODSA-N 0.000 description 1
- BIHMNDPWRUROFZ-JYJNAYRXSA-N Glu-His-Phe Chemical compound [H]N[C@@H](CCC(O)=O)C(=O)N[C@@H](CC1=CNC=N1)C(=O)N[C@@H](CC1=CC=CC=C1)C(O)=O BIHMNDPWRUROFZ-JYJNAYRXSA-N 0.000 description 1
- VGOFRWOTSXVPAU-SDDRHHMPSA-N Glu-His-Pro Chemical compound C1C[C@@H](N(C1)C(=O)[C@H](CC2=CN=CN2)NC(=O)[C@H](CCC(=O)O)N)C(=O)O VGOFRWOTSXVPAU-SDDRHHMPSA-N 0.000 description 1
- CUPSDFQZTVVTSK-GUBZILKMSA-N Glu-Lys-Asp Chemical compound OC(=O)C[C@@H](C(O)=O)NC(=O)[C@H](CCCCN)NC(=O)[C@@H](N)CCC(O)=O CUPSDFQZTVVTSK-GUBZILKMSA-N 0.000 description 1
- GTFYQOVVVJASOA-ACZMJKKPSA-N Glu-Ser-Cys Chemical compound C(CC(=O)O)[C@@H](C(=O)N[C@@H](CO)C(=O)N[C@@H](CS)C(=O)O)N GTFYQOVVVJASOA-ACZMJKKPSA-N 0.000 description 1
- ZAPFAWQHBOHWLL-GUBZILKMSA-N Glu-Ser-His Chemical compound C1=C(NC=N1)C[C@@H](C(=O)O)NC(=O)[C@H](CO)NC(=O)[C@H](CCC(=O)O)N ZAPFAWQHBOHWLL-GUBZILKMSA-N 0.000 description 1
- XQHSBNVACKQWAV-WHFBIAKZSA-N Gly-Asp-Asn Chemical compound [H]NCC(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H](CC(N)=O)C(O)=O XQHSBNVACKQWAV-WHFBIAKZSA-N 0.000 description 1
- UQJNXZSSGQIPIQ-FBCQKBJTSA-N Gly-Gly-Thr Chemical compound C[C@@H](O)[C@@H](C(O)=O)NC(=O)CNC(=O)CN UQJNXZSSGQIPIQ-FBCQKBJTSA-N 0.000 description 1
- INLIXXRWNUKVCF-JTQLQIEISA-N Gly-Gly-Tyr Chemical compound NCC(=O)NCC(=O)N[C@H](C(O)=O)CC1=CC=C(O)C=C1 INLIXXRWNUKVCF-JTQLQIEISA-N 0.000 description 1
- SCWYHUQOOFRVHP-MBLNEYKQSA-N Gly-Ile-Thr Chemical compound NCC(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H]([C@@H](C)O)C(O)=O SCWYHUQOOFRVHP-MBLNEYKQSA-N 0.000 description 1
- CCBIBMKQNXHNIN-ZETCQYMHSA-N Gly-Leu-Gly Chemical compound NCC(=O)N[C@@H](CC(C)C)C(=O)NCC(O)=O CCBIBMKQNXHNIN-ZETCQYMHSA-N 0.000 description 1
- WNZOCXUOGVYYBJ-CDMKHQONSA-N Gly-Phe-Thr Chemical compound C[C@H]([C@@H](C(=O)O)NC(=O)[C@H](CC1=CC=CC=C1)NC(=O)CN)O WNZOCXUOGVYYBJ-CDMKHQONSA-N 0.000 description 1
- LBDXVCBAJJNJNN-WHFBIAKZSA-N Gly-Ser-Cys Chemical compound NCC(=O)N[C@@H](CO)C(=O)N[C@@H](CS)C(O)=O LBDXVCBAJJNJNN-WHFBIAKZSA-N 0.000 description 1
- POJJAZJHBGXEGM-YUMQZZPRSA-N Gly-Ser-Lys Chemical compound C(CCN)C[C@@H](C(=O)O)NC(=O)[C@H](CO)NC(=O)CN POJJAZJHBGXEGM-YUMQZZPRSA-N 0.000 description 1
- XHVONGZZVUUORG-WEDXCCLWSA-N Gly-Thr-Lys Chemical compound NCC(=O)N[C@@H]([C@H](O)C)C(=O)N[C@H](C(O)=O)CCCCN XHVONGZZVUUORG-WEDXCCLWSA-N 0.000 description 1
- HQKADFMLECZIQJ-HVTMNAMFSA-N His-Glu-Ile Chemical compound CC[C@H](C)[C@@H](C(=O)O)NC(=O)[C@H](CCC(=O)O)NC(=O)[C@H](CC1=CN=CN1)N HQKADFMLECZIQJ-HVTMNAMFSA-N 0.000 description 1
- KFQDSSNYWKZFOO-LSJOCFKGSA-N His-Val-Ala Chemical compound [H]N[C@@H](CC1=CNC=N1)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](C)C(O)=O KFQDSSNYWKZFOO-LSJOCFKGSA-N 0.000 description 1
- UAVQIQOOBXFKRC-BYULHYEWSA-N Ile-Asn-Gly Chemical compound CC[C@H](C)[C@H](N)C(=O)N[C@@H](CC(N)=O)C(=O)NCC(O)=O UAVQIQOOBXFKRC-BYULHYEWSA-N 0.000 description 1
- BGZIJZJBXRVBGJ-SXTJYALSSA-N Ile-Asp-Ile Chemical compound CC[C@H](C)[C@@H](C(=O)N[C@@H](CC(=O)O)C(=O)N[C@@H]([C@@H](C)CC)C(=O)O)N BGZIJZJBXRVBGJ-SXTJYALSSA-N 0.000 description 1
- VOBYAKCXGQQFLR-LSJOCFKGSA-N Ile-Gly-Val Chemical compound CC[C@H](C)[C@H](N)C(=O)NCC(=O)N[C@@H](C(C)C)C(O)=O VOBYAKCXGQQFLR-LSJOCFKGSA-N 0.000 description 1
- PWDSHAAAFXISLE-SXTJYALSSA-N Ile-Ile-Asp Chemical compound CC[C@H](C)[C@H](N)C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H](CC(O)=O)C(O)=O PWDSHAAAFXISLE-SXTJYALSSA-N 0.000 description 1
- ADDYYRVQQZFIMW-MNXVOIDGSA-N Ile-Lys-Glu Chemical compound CC[C@H](C)[C@@H](C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CCC(=O)O)C(=O)O)N ADDYYRVQQZFIMW-MNXVOIDGSA-N 0.000 description 1
- 108010065920 Insulin Lispro Proteins 0.000 description 1
- 108090000862 Ion Channels Proteins 0.000 description 1
- 102000004310 Ion Channels Human genes 0.000 description 1
- 239000012880 LB liquid culture medium Substances 0.000 description 1
- WSGXUIQTEZDVHJ-GARJFASQSA-N Leu-Ala-Pro Chemical compound CC(C)C[C@H](N)C(=O)N[C@@H](C)C(=O)N1CCC[C@@H]1C(O)=O WSGXUIQTEZDVHJ-GARJFASQSA-N 0.000 description 1
- XYUBOFCTGPZFSA-WDSOQIARSA-N Leu-Arg-Trp Chemical compound C1=CC=C2C(C[C@H](NC(=O)[C@H](CCCN=C(N)N)NC(=O)[C@@H](N)CC(C)C)C(O)=O)=CNC2=C1 XYUBOFCTGPZFSA-WDSOQIARSA-N 0.000 description 1
- ULXYQAJWJGLCNR-YUMQZZPRSA-N Leu-Asp-Gly Chemical compound CC(C)C[C@H](N)C(=O)N[C@@H](CC(O)=O)C(=O)NCC(O)=O ULXYQAJWJGLCNR-YUMQZZPRSA-N 0.000 description 1
- IIKJNQWOQIWWMR-CIUDSAMLSA-N Leu-Cys-Ala Chemical compound C[C@@H](C(=O)O)NC(=O)[C@H](CS)NC(=O)[C@H](CC(C)C)N IIKJNQWOQIWWMR-CIUDSAMLSA-N 0.000 description 1
- OXRLYTYUXAQTHP-YUMQZZPRSA-N Leu-Gly-Ala Chemical compound [H]N[C@@H](CC(C)C)C(=O)NCC(=O)N[C@@H](C)C(O)=O OXRLYTYUXAQTHP-YUMQZZPRSA-N 0.000 description 1
- LXKNSJLSGPNHSK-KKUMJFAQSA-N Leu-Leu-Lys Chemical compound CC(C)C[C@@H](C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCCCN)C(=O)O)N LXKNSJLSGPNHSK-KKUMJFAQSA-N 0.000 description 1
- ZAVCJRJOQKIOJW-KKUMJFAQSA-N Leu-Phe-Asp Chemical compound CC(C)C[C@H](N)C(=O)N[C@H](C(=O)N[C@@H](CC(O)=O)C(O)=O)CC1=CC=CC=C1 ZAVCJRJOQKIOJW-KKUMJFAQSA-N 0.000 description 1
- YESNGRDJQWDYLH-KKUMJFAQSA-N Leu-Phe-Cys Chemical compound CC(C)C[C@@H](C(=O)N[C@@H](CC1=CC=CC=C1)C(=O)N[C@@H](CS)C(=O)O)N YESNGRDJQWDYLH-KKUMJFAQSA-N 0.000 description 1
- KWLWZYMNUZJKMZ-IHRRRGAJSA-N Leu-Pro-Leu Chemical compound CC(C)C[C@H](N)C(=O)N1CCC[C@H]1C(=O)N[C@@H](CC(C)C)C(O)=O KWLWZYMNUZJKMZ-IHRRRGAJSA-N 0.000 description 1
- JDBQSGMJBMPNFT-AVGNSLFASA-N Leu-Pro-Val Chemical compound CC(C)C[C@H](N)C(=O)N1CCC[C@H]1C(=O)N[C@@H](C(C)C)C(O)=O JDBQSGMJBMPNFT-AVGNSLFASA-N 0.000 description 1
- SBANPBVRHYIMRR-GARJFASQSA-N Leu-Ser-Pro Chemical compound CC(C)C[C@@H](C(=O)N[C@@H](CO)C(=O)N1CCC[C@@H]1C(=O)O)N SBANPBVRHYIMRR-GARJFASQSA-N 0.000 description 1
- SBANPBVRHYIMRR-UHFFFAOYSA-N Leu-Ser-Pro Natural products CC(C)CC(N)C(=O)NC(CO)C(=O)N1CCCC1C(O)=O SBANPBVRHYIMRR-UHFFFAOYSA-N 0.000 description 1
- QQXJROOJCMIHIV-AVGNSLFASA-N Leu-Val-Met Chemical compound [H]N[C@@H](CC(C)C)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](CCSC)C(O)=O QQXJROOJCMIHIV-AVGNSLFASA-N 0.000 description 1
- SJNZALDHDUYDBU-IHRRRGAJSA-N Lys-Arg-Lys Chemical compound NCCCC[C@H](N)C(=O)N[C@@H](CCCN=C(N)N)C(=O)N[C@@H](CCCCN)C(O)=O SJNZALDHDUYDBU-IHRRRGAJSA-N 0.000 description 1
- ITWQLSZTLBKWJM-YUMQZZPRSA-N Lys-Gly-Ala Chemical compound OC(=O)[C@H](C)NC(=O)CNC(=O)[C@@H](N)CCCCN ITWQLSZTLBKWJM-YUMQZZPRSA-N 0.000 description 1
- GQZMPWBZQALKJO-UWVGGRQHSA-N Lys-Gly-Arg Chemical compound [H]N[C@@H](CCCCN)C(=O)NCC(=O)N[C@@H](CCCNC(N)=N)C(O)=O GQZMPWBZQALKJO-UWVGGRQHSA-N 0.000 description 1
- SQJSXOQXJYAVRV-SRVKXCTJSA-N Lys-His-Asn Chemical compound C1=C(NC=N1)C[C@@H](C(=O)N[C@@H](CC(=O)N)C(=O)O)NC(=O)[C@H](CCCCN)N SQJSXOQXJYAVRV-SRVKXCTJSA-N 0.000 description 1
- VMTYLUGCXIEDMV-QWRGUYRKSA-N Lys-Leu-Gly Chemical compound OC(=O)CNC(=O)[C@H](CC(C)C)NC(=O)[C@@H](N)CCCCN VMTYLUGCXIEDMV-QWRGUYRKSA-N 0.000 description 1
- AIRZWUMAHCDDHR-KKUMJFAQSA-N Lys-Leu-Leu Chemical compound [H]N[C@@H](CCCCN)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CC(C)C)C(O)=O AIRZWUMAHCDDHR-KKUMJFAQSA-N 0.000 description 1
- 108010026217 Malate Dehydrogenase Proteins 0.000 description 1
- 102000013460 Malate Dehydrogenase Human genes 0.000 description 1
- 108090000301 Membrane transport proteins Proteins 0.000 description 1
- 102000003939 Membrane transport proteins Human genes 0.000 description 1
- NKDSBBBPGIVWEI-RCWTZXSCSA-N Met-Arg-Thr Chemical compound [H]N[C@@H](CCSC)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H]([C@@H](C)O)C(O)=O NKDSBBBPGIVWEI-RCWTZXSCSA-N 0.000 description 1
- NLHSFJQUHGCWSD-PYJNHQTQSA-N Met-Ile-His Chemical compound N[C@@H](CCSC)C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H](CC1=CNC=N1)C(O)=O NLHSFJQUHGCWSD-PYJNHQTQSA-N 0.000 description 1
- UROWNMBTQGGTHB-DCAQKATOSA-N Met-Leu-Asp Chemical compound CSCC[C@H](N)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CC(O)=O)C(O)=O UROWNMBTQGGTHB-DCAQKATOSA-N 0.000 description 1
- KZKVVWBOGDKHKE-QTKMDUPCSA-N Met-Thr-His Chemical compound CSCC[C@H](N)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@H](C(O)=O)CC1=CNC=N1 KZKVVWBOGDKHKE-QTKMDUPCSA-N 0.000 description 1
- YGNUDKAPJARTEM-GUBZILKMSA-N Met-Val-Ala Chemical compound CSCC[C@H](N)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](C)C(O)=O YGNUDKAPJARTEM-GUBZILKMSA-N 0.000 description 1
- YBAFDPFAUTYYRW-UHFFFAOYSA-N N-L-alpha-glutamyl-L-leucine Natural products CC(C)CC(C(O)=O)NC(=O)C(N)CCC(O)=O YBAFDPFAUTYYRW-UHFFFAOYSA-N 0.000 description 1
- SITLTJHOQZFJGG-UHFFFAOYSA-N N-L-alpha-glutamyl-L-valine Natural products CC(C)C(C(O)=O)NC(=O)C(N)CCC(O)=O SITLTJHOQZFJGG-UHFFFAOYSA-N 0.000 description 1
- 108010036197 NAD phosphite oxidoreductase Proteins 0.000 description 1
- 108010065395 Neuropep-1 Proteins 0.000 description 1
- BJEYSVHMGIJORT-NHCYSSNCSA-N Phe-Ala-Ala Chemical compound OC(=O)[C@H](C)NC(=O)[C@H](C)NC(=O)[C@@H](N)CC1=CC=CC=C1 BJEYSVHMGIJORT-NHCYSSNCSA-N 0.000 description 1
- JJHVFCUWLSKADD-ONGXEEELSA-N Phe-Gly-Ala Chemical compound [H]N[C@@H](CC1=CC=CC=C1)C(=O)NCC(=O)N[C@@H](C)C(O)=O JJHVFCUWLSKADD-ONGXEEELSA-N 0.000 description 1
- OVJMCXAPGFDGMG-HKUYNNGSSA-N Phe-Gly-Trp Chemical compound [H]N[C@@H](CC1=CC=CC=C1)C(=O)NCC(=O)N[C@@H](CC1=CNC2=C1C=CC=C2)C(O)=O OVJMCXAPGFDGMG-HKUYNNGSSA-N 0.000 description 1
- YTILBRIUASDGBL-BZSNNMDCSA-N Phe-Leu-Leu Chemical compound CC(C)C[C@@H](C(O)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@@H](N)CC1=CC=CC=C1 YTILBRIUASDGBL-BZSNNMDCSA-N 0.000 description 1
- KLXQWABNAWDRAY-ACRUOGEOSA-N Phe-Lys-Phe Chemical compound C([C@H](N)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CC=1C=CC=CC=1)C(O)=O)C1=CC=CC=C1 KLXQWABNAWDRAY-ACRUOGEOSA-N 0.000 description 1
- XROLYVMNVIKVEM-BQBZGAKWSA-N Pro-Asn-Gly Chemical compound [H]N1CCC[C@H]1C(=O)N[C@@H](CC(N)=O)C(=O)NCC(O)=O XROLYVMNVIKVEM-BQBZGAKWSA-N 0.000 description 1
- VOZIBWWZSBIXQN-SRVKXCTJSA-N Pro-Glu-Lys Chemical compound NCCCC[C@H](NC(=O)[C@H](CCC(O)=O)NC(=O)[C@@H]1CCCN1)C(O)=O VOZIBWWZSBIXQN-SRVKXCTJSA-N 0.000 description 1
- MRYUJHGPZQNOAD-IHRRRGAJSA-N Pro-Leu-Lys Chemical compound CC(C)C[C@@H](C(=O)N[C@@H](CCCCN)C(=O)O)NC(=O)[C@@H]1CCCN1 MRYUJHGPZQNOAD-IHRRRGAJSA-N 0.000 description 1
- SXMSEHDMNIUTSP-DCAQKATOSA-N Pro-Lys-Asn Chemical compound [H]N1CCC[C@H]1C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CC(N)=O)C(O)=O SXMSEHDMNIUTSP-DCAQKATOSA-N 0.000 description 1
- JIWJRKNYLSHONY-KKUMJFAQSA-N Pro-Phe-Glu Chemical compound [H]N1CCC[C@H]1C(=O)N[C@@H](CC1=CC=CC=C1)C(=O)N[C@@H](CCC(O)=O)C(O)=O JIWJRKNYLSHONY-KKUMJFAQSA-N 0.000 description 1
- NLQUOHDCLSFABG-GUBZILKMSA-N Ser-Arg-Arg Chemical compound NC(N)=NCCC[C@H](NC(=O)[C@H](CO)N)C(=O)N[C@@H](CCCN=C(N)N)C(O)=O NLQUOHDCLSFABG-GUBZILKMSA-N 0.000 description 1
- BTPAWKABYQMKKN-LKXGYXEUSA-N Ser-Asp-Thr Chemical compound [H]N[C@@H](CO)C(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H]([C@@H](C)O)C(O)=O BTPAWKABYQMKKN-LKXGYXEUSA-N 0.000 description 1
- BRGQQXQKPUCUJQ-KBIXCLLPSA-N Ser-Glu-Ile Chemical compound [H]N[C@@H](CO)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H]([C@@H](C)CC)C(O)=O BRGQQXQKPUCUJQ-KBIXCLLPSA-N 0.000 description 1
- VQBCMLMPEWPUTB-ACZMJKKPSA-N Ser-Glu-Ser Chemical compound [H]N[C@@H](CO)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CO)C(O)=O VQBCMLMPEWPUTB-ACZMJKKPSA-N 0.000 description 1
- MQQBBLVOUUJKLH-HJPIBITLSA-N Ser-Ile-Tyr Chemical compound [H]N[C@@H](CO)C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H](CC1=CC=C(O)C=C1)C(O)=O MQQBBLVOUUJKLH-HJPIBITLSA-N 0.000 description 1
- VMLONWHIORGALA-SRVKXCTJSA-N Ser-Leu-Leu Chemical compound CC(C)C[C@@H](C([O-])=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@@H]([NH3+])CO VMLONWHIORGALA-SRVKXCTJSA-N 0.000 description 1
- VUVCRYXYUUPGSB-GLLZPBPUSA-N Thr-Gln-Glu Chemical compound C[C@H]([C@@H](C(=O)N[C@@H](CCC(=O)N)C(=O)N[C@@H](CCC(=O)O)C(=O)O)N)O VUVCRYXYUUPGSB-GLLZPBPUSA-N 0.000 description 1
- QQWNRERCGGZOKG-WEDXCCLWSA-N Thr-Gly-Leu Chemical compound [H]N[C@@H]([C@@H](C)O)C(=O)NCC(=O)N[C@@H](CC(C)C)C(O)=O QQWNRERCGGZOKG-WEDXCCLWSA-N 0.000 description 1
- CRZNCABIJLRFKZ-IUKAMOBKSA-N Thr-Ile-Asp Chemical compound CC[C@H](C)[C@@H](C(=O)N[C@@H](CC(=O)O)C(=O)O)NC(=O)[C@H]([C@@H](C)O)N CRZNCABIJLRFKZ-IUKAMOBKSA-N 0.000 description 1
- PELIQFPESHBTMA-WLTAIBSBSA-N Thr-Tyr-Gly Chemical compound C[C@@H](O)[C@H](N)C(=O)N[C@H](C(=O)NCC(O)=O)CC1=CC=C(O)C=C1 PELIQFPESHBTMA-WLTAIBSBSA-N 0.000 description 1
- CYCGARJWIQWPQM-YJRXYDGGSA-N Thr-Tyr-Ser Chemical compound C[C@@H](O)[C@H]([NH3+])C(=O)N[C@H](C(=O)N[C@@H](CO)C([O-])=O)CC1=CC=C(O)C=C1 CYCGARJWIQWPQM-YJRXYDGGSA-N 0.000 description 1
- QNXZCKMXHPULME-ZNSHCXBVSA-N Thr-Val-Pro Chemical compound C[C@H]([C@@H](C(=O)N[C@@H](C(C)C)C(=O)N1CCC[C@@H]1C(=O)O)N)O QNXZCKMXHPULME-ZNSHCXBVSA-N 0.000 description 1
- KCPFDGNYAMKZQP-KBPBESRZSA-N Tyr-Gly-Leu Chemical compound [H]N[C@@H](CC1=CC=C(O)C=C1)C(=O)NCC(=O)N[C@@H](CC(C)C)C(O)=O KCPFDGNYAMKZQP-KBPBESRZSA-N 0.000 description 1
- SOEGLGLDSUHWTI-STECZYCISA-N Tyr-Pro-Ile Chemical compound CC[C@H](C)[C@@H](C(O)=O)NC(=O)[C@@H]1CCCN1C(=O)[C@@H](N)CC1=CC=C(O)C=C1 SOEGLGLDSUHWTI-STECZYCISA-N 0.000 description 1
- ZXAGTABZUOMUDO-GVXVVHGQSA-N Val-Glu-Lys Chemical compound CC(C)[C@@H](C(=O)N[C@@H](CCC(=O)O)C(=O)N[C@@H](CCCCN)C(=O)O)N ZXAGTABZUOMUDO-GVXVVHGQSA-N 0.000 description 1
- CELJCNRXKZPTCX-XPUUQOCRSA-N Val-Gly-Ala Chemical compound CC(C)[C@H](N)C(=O)NCC(=O)N[C@@H](C)C(O)=O CELJCNRXKZPTCX-XPUUQOCRSA-N 0.000 description 1
- PMDOQZFYGWZSTK-LSJOCFKGSA-N Val-Gly-Ile Chemical compound CC[C@H](C)[C@@H](C(O)=O)NC(=O)CNC(=O)[C@@H](N)C(C)C PMDOQZFYGWZSTK-LSJOCFKGSA-N 0.000 description 1
- URIRWLJVWHYLET-ONGXEEELSA-N Val-Gly-Leu Chemical compound CC(C)C[C@@H](C(O)=O)NC(=O)CNC(=O)[C@@H](N)C(C)C URIRWLJVWHYLET-ONGXEEELSA-N 0.000 description 1
- XXROXFHCMVXETG-UWVGGRQHSA-N Val-Gly-Val Chemical compound CC(C)[C@H](N)C(=O)NCC(=O)N[C@@H](C(C)C)C(O)=O XXROXFHCMVXETG-UWVGGRQHSA-N 0.000 description 1
- RWOGENDAOGMHLX-DCAQKATOSA-N Val-Lys-Ala Chemical compound C[C@@H](C(=O)O)NC(=O)[C@H](CCCCN)NC(=O)[C@H](C(C)C)N RWOGENDAOGMHLX-DCAQKATOSA-N 0.000 description 1
- IEBGHUMBJXIXHM-AVGNSLFASA-N Val-Lys-Met Chemical compound CC(C)[C@@H](C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CCSC)C(=O)O)N IEBGHUMBJXIXHM-AVGNSLFASA-N 0.000 description 1
- VPGCVZRRBYOGCD-AVGNSLFASA-N Val-Lys-Val Chemical compound CC(C)[C@H](N)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](C(C)C)C(O)=O VPGCVZRRBYOGCD-AVGNSLFASA-N 0.000 description 1
- SJRUJQFQVLMZFW-WPRPVWTQSA-N Val-Pro-Gly Chemical compound CC(C)[C@H](N)C(=O)N1CCC[C@H]1C(=O)NCC(O)=O SJRUJQFQVLMZFW-WPRPVWTQSA-N 0.000 description 1
- UVHFONIHVHLDDQ-IFFSRLJSSA-N Val-Thr-Glu Chemical compound C[C@H]([C@@H](C(=O)N[C@@H](CCC(=O)O)C(=O)O)NC(=O)[C@H](C(C)C)N)O UVHFONIHVHLDDQ-IFFSRLJSSA-N 0.000 description 1
- HTONZBWRYUKUKC-RCWTZXSCSA-N Val-Thr-Val Chemical compound CC(C)[C@H](N)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](C(C)C)C(O)=O HTONZBWRYUKUKC-RCWTZXSCSA-N 0.000 description 1
- 229930003761 Vitamin B9 Natural products 0.000 description 1
- 108010047495 alanylglycine Proteins 0.000 description 1
- 108010087924 alanylproline Proteins 0.000 description 1
- 229960004050 aminobenzoic acid Drugs 0.000 description 1
- 229940043376 ammonium acetate Drugs 0.000 description 1
- 235000019257 ammonium acetate Nutrition 0.000 description 1
- 230000001195 anabolic effect Effects 0.000 description 1
- 108010062796 arginyllysine Proteins 0.000 description 1
- 108010069205 aspartyl-phenylalanine Proteins 0.000 description 1
- QVGXLLKOCUKJST-UHFFFAOYSA-N atomic oxygen Chemical compound [O] QVGXLLKOCUKJST-UHFFFAOYSA-N 0.000 description 1
- 238000005842 biochemical reaction Methods 0.000 description 1
- 229960002685 biotin Drugs 0.000 description 1
- 235000020958 biotin Nutrition 0.000 description 1
- 239000011616 biotin Substances 0.000 description 1
- DNZWLJIKNWYXJP-UHFFFAOYSA-N butan-1-ol;propan-2-one Chemical compound CC(C)=O.CCCCO DNZWLJIKNWYXJP-UHFFFAOYSA-N 0.000 description 1
- 229940041514 candida albicans extract Drugs 0.000 description 1
- 230000001925 catabolic effect Effects 0.000 description 1
- 230000015556 catabolic process Effects 0.000 description 1
- 230000019522 cellular metabolic process Effects 0.000 description 1
- 238000010367 cloning Methods 0.000 description 1
- 239000002131 composite material Substances 0.000 description 1
- 150000001875 compounds Chemical class 0.000 description 1
- 230000008878 coupling Effects 0.000 description 1
- 238000010168 coupling process Methods 0.000 description 1
- 108010004073 cysteinylcysteine Proteins 0.000 description 1
- 108010016616 cysteinylglycine Proteins 0.000 description 1
- 229940104302 cytosine Drugs 0.000 description 1
- 238000000354 decomposition reaction Methods 0.000 description 1
- ZPWVASYFFYYZEW-UHFFFAOYSA-L dipotassium hydrogen phosphate Chemical compound [K+].[K+].OP([O-])([O-])=O ZPWVASYFFYYZEW-UHFFFAOYSA-L 0.000 description 1
- 229910000396 dipotassium phosphate Inorganic materials 0.000 description 1
- 235000019797 dipotassium phosphate Nutrition 0.000 description 1
- 230000000694 effects Effects 0.000 description 1
- NLFBCYMMUAKCPC-KQQUZDAGSA-N ethyl (e)-3-[3-amino-2-cyano-1-[(e)-3-ethoxy-3-oxoprop-1-enyl]sulfanyl-3-oxoprop-1-enyl]sulfanylprop-2-enoate Chemical compound CCOC(=O)\C=C\SC(=C(C#N)C(N)=O)S\C=C\C(=O)OCC NLFBCYMMUAKCPC-KQQUZDAGSA-N 0.000 description 1
- 238000001914 filtration Methods 0.000 description 1
- OVBPIULPVIDEAO-LBPRGKRZSA-N folic acid Chemical compound C=1N=C2NC(N)=NC(=O)C2=NC=1CNC1=CC=C(C(=O)N[C@@H](CCC(O)=O)C(O)=O)C=C1 OVBPIULPVIDEAO-LBPRGKRZSA-N 0.000 description 1
- 238000003209 gene knockout Methods 0.000 description 1
- 238000003208 gene overexpression Methods 0.000 description 1
- 108010079547 glutamylmethionine Proteins 0.000 description 1
- VPZXBVLAVMBEQI-UHFFFAOYSA-N glycyl-DL-alpha-alanine Natural products OC(=O)C(C)NC(=O)CN VPZXBVLAVMBEQI-UHFFFAOYSA-N 0.000 description 1
- 108010020688 glycylhistidine Proteins 0.000 description 1
- 108010015792 glycyllysine Proteins 0.000 description 1
- 229910052736 halogen Inorganic materials 0.000 description 1
- 150000002367 halogens Chemical class 0.000 description 1
- 108010036413 histidylglycine Proteins 0.000 description 1
- 230000001939 inductive effect Effects 0.000 description 1
- 239000002054 inoculum Substances 0.000 description 1
- SURQXAFEQWPFPV-UHFFFAOYSA-L iron(2+) sulfate heptahydrate Chemical compound O.O.O.O.O.O.O.[Fe+2].[O-]S([O-])(=O)=O SURQXAFEQWPFPV-UHFFFAOYSA-L 0.000 description 1
- BPHPUYQFMNQIOC-NXRLNHOXSA-N isopropyl beta-D-thiogalactopyranoside Chemical compound CC(C)S[C@@H]1O[C@H](CO)[C@H](O)[C@H](O)[C@H]1O BPHPUYQFMNQIOC-NXRLNHOXSA-N 0.000 description 1
- 210000002429 large intestine Anatomy 0.000 description 1
- 108010077158 leucinyl-arginyl-tryptophan Proteins 0.000 description 1
- 108010044311 leucyl-glycyl-glycine Proteins 0.000 description 1
- 108010034529 leucyl-lysine Proteins 0.000 description 1
- 108010090333 leucyl-lysyl-proline Proteins 0.000 description 1
- 108010047926 leucyl-lysyl-tyrosine Proteins 0.000 description 1
- WRUGWIBCXHJTDG-UHFFFAOYSA-L magnesium sulfate heptahydrate Chemical compound O.O.O.O.O.O.O.[Mg+2].[O-]S([O-])(=O)=O WRUGWIBCXHJTDG-UHFFFAOYSA-L 0.000 description 1
- 229940061634 magnesium sulfate heptahydrate Drugs 0.000 description 1
- 229940049920 malate Drugs 0.000 description 1
- BJEPYKJPYRNKOW-UHFFFAOYSA-N malic acid Chemical compound OC(=O)C(O)CC(O)=O BJEPYKJPYRNKOW-UHFFFAOYSA-N 0.000 description 1
- ISPYRSDWRDQNSW-UHFFFAOYSA-L manganese(II) sulfate monohydrate Chemical compound O.[Mn+2].[O-]S([O-])(=O)=O ISPYRSDWRDQNSW-UHFFFAOYSA-L 0.000 description 1
- 239000012528 membrane Substances 0.000 description 1
- 230000004060 metabolic process Effects 0.000 description 1
- 239000011259 mixed solution Substances 0.000 description 1
- 238000002156 mixing Methods 0.000 description 1
- 239000000203 mixture Substances 0.000 description 1
- 229910000402 monopotassium phosphate Inorganic materials 0.000 description 1
- 235000019796 monopotassium phosphate Nutrition 0.000 description 1
- 239000002773 nucleotide Substances 0.000 description 1
- 125000003729 nucleotide group Chemical group 0.000 description 1
- 230000001590 oxidative effect Effects 0.000 description 1
- 229910052760 oxygen Inorganic materials 0.000 description 1
- 239000001301 oxygen Substances 0.000 description 1
- GNSKLFRGEWLPPA-UHFFFAOYSA-M potassium dihydrogen phosphate Chemical compound [K+].OP(O)([O-])=O GNSKLFRGEWLPPA-UHFFFAOYSA-M 0.000 description 1
- 239000000843 powder Substances 0.000 description 1
- 108010029020 prolylglycine Proteins 0.000 description 1
- 108010053725 prolylvaline Proteins 0.000 description 1
- 102000004169 proteins and genes Human genes 0.000 description 1
- 230000009467 reduction Effects 0.000 description 1
- 238000002864 sequence alignment Methods 0.000 description 1
- 108010026333 seryl-proline Proteins 0.000 description 1
- 108010005652 splenotritin Proteins 0.000 description 1
- 230000001954 sterilising effect Effects 0.000 description 1
- 230000009466 transformation Effects 0.000 description 1
- 230000001131 transforming effect Effects 0.000 description 1
- 108010038745 tryptophylglycine Proteins 0.000 description 1
- 229910021642 ultra pure water Inorganic materials 0.000 description 1
- 239000012498 ultrapure water Substances 0.000 description 1
- 239000011727 vitamin B9 Substances 0.000 description 1
- 235000019159 vitamin B9 Nutrition 0.000 description 1
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 1
- 239000012138 yeast extract Substances 0.000 description 1
Images
Classifications
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12P—FERMENTATION OR ENZYME-USING PROCESSES TO SYNTHESISE A DESIRED CHEMICAL COMPOUND OR COMPOSITION OR TO SEPARATE OPTICAL ISOMERS FROM A RACEMIC MIXTURE
- C12P19/00—Preparation of compounds containing saccharide radicals
- C12P19/02—Monosaccharides
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12P—FERMENTATION OR ENZYME-USING PROCESSES TO SYNTHESISE A DESIRED CHEMICAL COMPOUND OR COMPOSITION OR TO SEPARATE OPTICAL ISOMERS FROM A RACEMIC MIXTURE
- C12P7/00—Preparation of oxygen-containing organic compounds
- C12P7/02—Preparation of oxygen-containing organic compounds containing a hydroxy group
- C12P7/04—Preparation of oxygen-containing organic compounds containing a hydroxy group acyclic
- C12P7/06—Ethanol, i.e. non-beverage
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12P—FERMENTATION OR ENZYME-USING PROCESSES TO SYNTHESISE A DESIRED CHEMICAL COMPOUND OR COMPOSITION OR TO SEPARATE OPTICAL ISOMERS FROM A RACEMIC MIXTURE
- C12P7/00—Preparation of oxygen-containing organic compounds
- C12P7/02—Preparation of oxygen-containing organic compounds containing a hydroxy group
- C12P7/04—Preparation of oxygen-containing organic compounds containing a hydroxy group acyclic
- C12P7/06—Ethanol, i.e. non-beverage
- C12P7/065—Ethanol, i.e. non-beverage with microorganisms other than yeasts
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12P—FERMENTATION OR ENZYME-USING PROCESSES TO SYNTHESISE A DESIRED CHEMICAL COMPOUND OR COMPOSITION OR TO SEPARATE OPTICAL ISOMERS FROM A RACEMIC MIXTURE
- C12P7/00—Preparation of oxygen-containing organic compounds
- C12P7/02—Preparation of oxygen-containing organic compounds containing a hydroxy group
- C12P7/04—Preparation of oxygen-containing organic compounds containing a hydroxy group acyclic
- C12P7/16—Butanols
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12P—FERMENTATION OR ENZYME-USING PROCESSES TO SYNTHESISE A DESIRED CHEMICAL COMPOUND OR COMPOSITION OR TO SEPARATE OPTICAL ISOMERS FROM A RACEMIC MIXTURE
- C12P7/00—Preparation of oxygen-containing organic compounds
- C12P7/24—Preparation of oxygen-containing organic compounds containing a carbonyl group
- C12P7/26—Ketones
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
- Y02E—REDUCTION OF GREENHOUSE GAS [GHG] EMISSIONS, RELATED TO ENERGY GENERATION, TRANSMISSION OR DISTRIBUTION
- Y02E50/00—Technologies for the production of fuel of non-fossil origin
- Y02E50/10—Biofuels, e.g. bio-diesel
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
- Y02P—CLIMATE CHANGE MITIGATION TECHNOLOGIES IN THE PRODUCTION OR PROCESSING OF GOODS
- Y02P20/00—Technologies relating to chemical industry
- Y02P20/50—Improvements relating to the production of bulk chemicals
- Y02P20/584—Recycling of catalysts
Landscapes
- Organic Chemistry (AREA)
- Chemical & Material Sciences (AREA)
- Engineering & Computer Science (AREA)
- Zoology (AREA)
- Life Sciences & Earth Sciences (AREA)
- Wood Science & Technology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Microbiology (AREA)
- General Chemical & Material Sciences (AREA)
- Biotechnology (AREA)
- Health & Medical Sciences (AREA)
- Biochemistry (AREA)
- Bioinformatics & Cheminformatics (AREA)
- General Engineering & Computer Science (AREA)
- General Health & Medical Sciences (AREA)
- Genetics & Genomics (AREA)
- Preparation Of Compounds By Using Micro-Organisms (AREA)
Abstract
The invention discloses an oxidation method using whole cells as a catalyst, and bridged flavin is used as intracellular NAD (P)+Regenerated catalyst, and intracellular NAD (P) -dependent+Coupled to the redox-enzyme-catalyzed oxidation reaction of (a) to form intracellular NAD (P)+And (4) regenerating a circulating system. Compared with the prior art for regulating and controlling the balance of intracellular cofactors based on an artificial cofactor system, the method does not need to construct a mutant enzyme library to identify the artificial cofactors, does not need to express membrane proteins which can generate toxicity to cells, has strong applicability, can be coupled with a plurality of intracellular oxidoreductase depending on NAD (P) +, and accelerates the regeneration of intracellular NAD (P) +; bridged flavin can enter the cell interior under the condition of not changing the permeability of a cell membrane or over-expressing a membrane protein, and the regeneration of intracellular nicotinamide cofactor is accelerated.
Description
Technical Field
The invention relates to redox reactions, in particular to an oxidation method using whole cells as a catalyst.
Background
The cofactor provides a redox carrier for biosynthesis and decomposition reactions, and is an important factor for energy transfer in cells, so that the cofactor has an important role in biochemical reactions. Cofactor NADH/NAD+And NADPH/NADP+As the most important redox carrier in cell metabolism, it can be used not only as an electron acceptor for catalyzing substrate catabolism but also as an electron acceptorThe amount-dependent redox reaction provides the reducing power. Thus, NADH/NAD+And NADPH/NADP+The balance of oxidation and reduction rates of (a) is a necessary requirement to maintain a normal anabolic and catabolic balance. By reasonably controlling the level of the intracellular cofactor, the biocatalysis process can be carried out more efficiently. Currently, there are three more commonly used strategies for controlling cofactor balance: 1) endogenous cofactor balance regulation means by methods of gene knockout or overexpression and the like; 2) an exogenous cofactor balance regulation and control means by introducing exogenous regenerated cofactor enzyme and other methods; 3) the preference of the cofactor is changed by methods such as protein engineering.
Another novel strategy is to construct an artificial cofactor system for regulation. Compared with natural cofactors, the artificial cofactors have the characteristics of high stability, easy preparation and relatively low price, and the catalytic efficiency is superior to that of the natural cofactors in certain enzymatic reactions, thereby providing a more efficient and lower-price way for regulating and controlling the balance of the cofactors. However, the application of artificial cofactors is still in the extracellular phase, and only one example of the application of artificial cofactors participating in intracellular metabolism is shown, and the group of Zhao Zong K.has constructed a selective electron transport system using Nicotinamide Cytosine Dinucleotide (NCD), an artificially synthesized natural nicotinamide cofactor analog, which can enter E.coli cells and be used by malate dehydrogenase and phosphite dehydrogenase that are mutated to recognize the artificial cofactors, to efficiently produce malate. However, such an artificial cofactor-based intracellular system requires the construction of a mutant enzyme library for identifying the artificial cofactor and the overexpression of the membrane transporter Ndt for transporting the artificial cofactor into the cell, and thus the artificial cofactor system has no broad spectrum and also the expression of the membrane channel protein causes toxicity to the cell.
Disclosure of Invention
The purpose of the invention is as follows: in order to solve the problem that the level of a cofactor in cells is not easy to regulate and control and influences the efficiency of redox reaction, the invention provides an oxidation method by using whole cells as a catalyst.
Technical methodA scheme: the invention relates to an oxidation method using whole cells as a catalyst, and bridged flavin is used as intracellular NAD (P)+Regenerated catalyst, and intracellular NAD (P) -dependent+Coupled to the redox-enzyme-catalyzed oxidation reaction of (a) to form intracellular NAD (P)+And (4) regenerating a circulating system. The inventor firstly discovers that bridged flavin can enter the interior of a cell under the condition of not changing the permeability of a cell membrane or over-expressing a membrane protein, and accelerates the NAD (P) in the cell+Regeneration; wherein NAD (P)+The regeneration of (a) needs to be accomplished under an atmosphere of air or oxygen.
Intracellular NAD (P)+The reaction process for regeneration is as follows: intracellular dependence on NAD (P)+The redox enzyme of (2) catalyzes the oxidation of the substrate, NAD (P)+Reduced to NAD (P) H with bridged flavins as NAD (P)+Regenerating the catalyst, oxidizing NAD (P) H to NAD (P)+Formation of intracellular NAD (P)+And a circulating system is regenerated, and the redox enzyme is assisted to continuously catalyze the substrate to carry out oxidation reaction. NAD (P) according to the invention+Is NAD+Or NADP+(ii) a The NAD (P) H is NADH or NADPH.
In particular, the catalytic system comprises whole cells, NAD (P) -dependent+The oxidoreductase substrate of (2), bridged flavins, buffer, the catalytic system being dependent on NAD (P)+The substrate of the oxidoreductase (2) undergoes an oxidation reaction. Preferably, after the oxidation reaction is finished, the solid-liquid separation is carried out on the catalytic system, and NAD (P) -dependent) is supplemented into the obtained precipitate+The oxidation reaction is continued by using the substrate of the oxidoreductase and the buffer solution, and the whole cells and bridged flavin are reused for 3 to 8 times. Preferably 5 times.
In another case, the catalytic system comprises whole cells, bridged flavins, a cell culture fluid comprising NAD (P) -dependent+The catalytic system catalyzes the dependence on NAD (P)+The substrate of the oxidoreductase (2) undergoes an oxidation reaction. After the oxidation reaction is finished, carrying out solid-liquid separation on the catalytic system, supplementing cell culture solution into the obtained precipitate, and continuing the oxidation reaction, wherein the whole cells and the bridged flavin are repeatedIt is applied 3-8 times. Preferably 5 times.
Preferably, the whole cell is selected from an Escherichia coli (Escherichia coli) cell, a yeast (saccharomyces) cell, a Clostridium acetobutylicum (Clostridium acetobutylicum) cell, a Corynebacterium glutamicum (Corynebacterium glutamicum) cell, a Bacillus subtilis (Bacillus subtilis) cell, a streptomyces (streptomyces cerevisiae) cell, an Aspergillus niger (Aspergillus niger) cell, or a recombinant cell of the above cells. More preferably, the whole cell is an Escherichia coli (Escherichia coli) cell or a recombinant Escherichia coli cell; more preferably recombinant E.coli MtDH-BL21 and GlyDH-BL 21.
Preferably, the whole cells are cells cultured to a logarithmic phase, a stationary phase or a decline phase using a liquid medium required for the respective cells; cells cultured to the log phase, stationary phase are preferred.
Preferably, the recombinant cell is a recombinant cell obtained by knocking out a cellular gene, expressing an endogenous gene or expressing an exogenous gene; recombinant cells expressing exogenous genes, overexpressing endogenous genes are preferred.
Preferably, the concentration of whole cells in the catalytic system is 0.01-100g/L, preferably 5-50g/L, more preferably 10 g/L.
The bridged flavin has the following structural general formula:
wherein R is1And R2Independently of one another, from: hydrogen, methyl, trifluoromethyl, methoxy, halogen atom, nitro and amino; r3Selected from: hydrogen, C1-C5 alkyl, phenyl and benzyl; x-Selected from: halide ion, nitrate radical, triflate ion. Preferably, R1Including but not limited to hydrogen, methyl, halogen atoms; r2Including but not limited to hydrogen, methyl, halogen, trifluoromethyl; r3Including but not limited to hydrogen, methyl; x-Is a halide ion.
More preferably, the bridged flavins include, but are not limited to, 7-trifluoromethyl-1, 10-ethylideneisoalloxazine chloride (compound II), 8-chloro-1, 10-ethylideneisoalloxazine chloride (compound III), or 1, 10-ethylideneisoalloxazine chloride (compound IV).
Most preferably, the bridged flavin is 7-trifluoromethyl-1, 10-ethylene isoalloxazine chloride.
The bridged flavins of the present invention may be synthesized by themselves with reference to the literature published at present, for example the literature [ Tetrahedron,2001,57, 4507-; or purchased directly from the market.
The concentration of bridged flavins in the catalytic system is 0.001-10mM, more preferably 0.05-0.5mM, more preferably 0.1-0.5mM, most preferably 0.1 mM.
Said dependence on NAD (P)+The oxidoreductase of (a) is selected from all enzymes of EC1.1.1.X, EC1.2.1.X, EC1.3.1.X, EC1.4.1.X, EC1.5.1.X, EC1.6.1.X, EC1.7.1.X, EC1.8.1.X, EC1.10.1.X, EC1.12.1.X, EC1.13.1.X, EC1.16.1.X, EC1.17.1.X, EC1.18.1.X, EC1.20.1.X, and EC1.22.1. X. The substrates are determined by different oxidoreductases.
Preferably, said dependence on NAD (P)+The oxidoreductase of (2) is mannitol dehydrogenase, glycerol dehydrogenase, alcohol dehydrogenase, or acetyl-CoA dehydrogenase.
Preferably, the catalytic system is NAD (P) -dependent+The initial concentration of substrate for the oxidoreductase of (3) is 50-1000 mM.
Preferably, the catalytic system further comprises an exogenously added NAD (P)+Said exogenously added NAD (P)+Is in a concentration of 0.05-5 mM.
Has the advantages that: (1) compared with the prior art for regulating and controlling the balance of intracellular cofactors based on an artificial cofactor system, the method does not need to construct a mutant enzyme library to identify the artificial cofactors, does not need to express membrane proteins which can generate toxicity to cells, has strong applicability, and can be used for regulating and controlling intracellular cofactor balance depending on NAD (P)+The oxidoreductase coupling of (2) accelerates intracellular NAD (P)+Regeneration; (2) the bridged flavin can enter the cell under the condition of not changing the permeability of a cell membrane or over-expressing a membrane protein, so that the regeneration of intracellular nicotinamide cofactor is accelerated; (3) the whole cells and bridged flavin in the catalytic system of the patent application can be recycled for 3-8 times under the condition of ensuring the product yield; (4) compared with in vitro bridged flavin mediated enzymatic reaction, the method has higher stability, and the steps of cell breaking and enzyme purification are omitted, so that the activity of the enzyme is ensured, and the cost for separating the enzyme is saved; (5) compared with the in vitro bridged flavin mediated enzymatic reaction, the method uses less or no natural nicotinamide cofactor, saves the reaction cost and has higher reaction efficiency than the in vitro reaction.
Drawings
FIG. 1 is a nucleotide sequence alignment chart of mannitol dehydrogenase genes before and after codon optimization;
FIG. 2 shows the use of 7-trifluoromethyl-1, 10-ethylene isoalloxazine chloride salt as intracellular NAD+Scheme for coupling reaction of regenerated catalyst with mannitol dehydrogenase expressed in E.coli cells.
Detailed Description
Example 1 optimization of mannitol dehydrogenase Gene
Analysis of rare codons: rare codons were mainly analyzed by the software e.coli Codon Usage Analysis 2.0 to obtain codons used with relative frequency below the threshold (10 ‰) in e.
Rare codons were optimized: codons with a frequency of usage below the threshold are optimized according to the frequency of usage of the different codons in e. The optimization results are shown in table 1:
TABLE 1 Pre-and post-optimization codon comparison
The application optimizes the mannitol dehydrogenase gene sequence according to the codon preference of escherichia coli, and the optimized sequence is shown as SEQ ID NO. 1. After comparison with DNMAN software, the homology between the modified sequence (MtDH) and the original sequence (MtDH _ Ag) was 73.35%, as shown in FIG. 1.
EXAMPLE 2 construction of recombinant E.coli MtDH-BL21 expressing mannitol dehydrogenase
The mannitol dehydrogenase gene MtDH optimized by the codon in the embodiment 1 is cloned to a pET-28a vector to obtain a recombinant plasmid pET-28a-MtDH, and then the recombinant plasmid is transformed into E.coli BL21 to obtain the recombinant Escherichia coli MtDH-BL21 of the over-expression MtDH gene.
Wherein, the vector plasmid pET-28a is purchased from Youbao organisms; coli BL21 was purchased from Takara corporation.
Gene MtDH and pET-28a vectors were recombined and then transformed into e.coli.bl21, preparation of relevant media, etc. according to the method of the third edition of molecular cloning experimental guidelines (huang peitang et al, china, scientific press, 2002); the primers required were all synthesized by Suzhou Jinweizhi Biotechnology, Inc.
Example 3 expression of recombinant E.coli MtDH-BL21
The recombinant E.coli MtDH-BL21 constructed in example 2 was inoculated in a volume ratio of 1% into a flask containing 200mL of LB liquid medium, cultured at 37 ℃ and 200rpm to OD600Reaching 0.6-0.8, adding IPTG with final concentration of 0.6mM into the culture solution, inducing at 25 deg.C and 200rpm for 12-16h, and centrifuging to obtain wet thallus of recombinant Escherichia coli.
The formula of the LB liquid culture medium is as follows: 10g/L of peptone, 5g/L of yeast extract and 10g/L of sodium chloride.
Example 4 7-trifluoromethyl-1, 10-ethylideneisoalloxazine chloride salt as regenerated NAD+The catalyst and recombinant Escherichia coli MtDH-BL21 are coupled to catalyze mannitol to prepare mannose
(1) Mannitol in 10mL of 100mM potassium phosphate buffer, pH9.5, at an initial concentration of 250mM, NAD+The recombinant Large intestine obtained in example 3 at a concentration of 1mM and a concentration of 0.1mM for 7-trifluoromethyl-1, 10-ethylideneisoalloxazineThe wet weight concentration of the bacillus MtDH-BL21 is 10g/L, and the reaction liquid is communicated with the outside air. The reaction was carried out at 25 ℃ and 150rpm for 24 hours, and the amount of mannose in the reaction system was measured to be 213mM after the completion of the reaction.
(2) Centrifuging the system obtained in the step (1), adding 10mL of 100mM potassium phosphate buffer solution with pH of 9.5 and mannitol into the obtained precipitate to make the initial concentration of the mannitol be 250mM, communicating the reaction solution with the outside air, and reacting at 25 ℃ and 150rpm for 24 h; the recombinant escherichia coli and the 7-trifluoromethyl-1, 10-ethylene isoalloxazine are repeatedly used for 5 times in a fed-batch mode, a substrate and a product are removed after each reaction is finished, and the mannose yield is 72% after the recombinant escherichia coli and the 7-trifluoromethyl-1, 10-ethylene isoalloxazine are repeatedly used for 5 times.
Example 51, 10-Ethyleneisoalloxazine chloride salt as regenerated NAD+The catalyst and recombinant Escherichia coli MtDH-BL21 are coupled to catalyze mannitol to prepare mannose
The procedure is as in example 4, except that bridged flavins are 1, 10-ethylene isoalloxazine chloride, at a concentration of 0.1 mM. The amount of mannose in the reaction system was measured at 168mM after the end of the reaction.
After the recombinant escherichia coli and the 1, 10-ethylene isoalloxazine chloride are repeatedly used for 5 times, the yield of mannose is 52 percent.
Example 6 8-chloro-1, 10-ethylene-based isoalloxazine chloride salt as regenerated NAD+The catalyst and recombinant Escherichia coli MtDH-BL21 are coupled to catalyze mannitol to prepare mannose
The procedure is as in example 4, except that bridged flavin is 8-chloro-1, 10-ethylene isoalloxazine chloride, at a concentration of 0.1 mM. The amount of mannose in the reaction system was 173mM as measured after the completion of the reaction.
After the recombinant escherichia coli and the 8-chloro-1, 10-ethylene isoalloxazine chloride are repeatedly used for 5 times, the yield of mannose is 61%.
Example 7 construction of recombinant E.coli GlyDH-BL21 expressing Glycerol dehydrogenase
Cloning a glycerol dehydrogenase gene GlyDH (GenBank: AAC43051.1) derived from E.coli K12 to a pET-28a vector to obtain a recombinant plasmid pET-28a-GlyDH, and then transforming the recombinant plasmid to E.coli BL21 to obtain the recombinant Escherichia coli GlyDH-BL21 capable of over-expressing the GlyDH gene.
Wherein, the vector plasmid pET-28a is purchased from Youbao organisms; coli BL21 was purchased from Takara corporation.
Gene GlyDH and pET-28a vector, then transformed into e.coli.bl21, preparation of relevant media, etc. according to the method of the third edition of molecular cloning protocols (yellow banking, et al, china, scientific press, 2002); the primers required were all synthesized by Suzhou Jinweizhi Biotechnology, Inc.
Example 8 expression of recombinant E.coli GlyDH-BL21
The expression method is the same as example 3, except that the recombinant Escherichia coli is GlyDH-BL 21.
Example 9 regeneration of intracellular NAD with 7-trifluoromethyl-1, 10-ethylideneisoalloxazine chloride salt+The catalyst is coupled with recombinant Escherichia coli GlyDH-BL21 to catalyze glycerol to prepare dihydroxyacetone DHA
(1) In 10mL of 100mM Tris-HCl buffer, pH9.5, the initial concentration of glycerol was 10g/L, NAD+The concentration was 5mM, the concentration of 7-trifluoromethyl-1, 10-ethylideneisoalloxazine was 0.1mM, the wet weight concentration of the recombinant E.coli GlyDH-BL21 obtained in example 8 was 10g/L, and the reaction solution was connected to the outside air. Reacting at 30 ℃ and 150rpm for 2 hours, and measuring the concentration of DHA in the reaction system to be 3.05g/L after the reaction is finished.
(2) The recombinant Escherichia coli GlyDH-BL21 and 7-trifluoromethyl-1, 10-ethylene isoalloxazine are repeatedly used for 5 times in a fed-batch mode, a substrate and a product are removed after each reaction is finished, and the DHA yield is 27% after the recombinant Escherichia coli GlyDH-BL21 and 7-trifluoromethyl-1, 10-ethylene isoalloxazine are repeatedly used for 5 times.
Example 10 construction of recombinant Bacillus subtilis MtDH-Bs168 expressing mannitol dehydrogenase
The mannitol dehydrogenase gene MtDH optimized by the codon in the embodiment 1 is cloned to a pMA5 vector to obtain a recombinant plasmid pMA5-MtDH, and then the recombinant plasmid is transformed into Bacillus subtilis B.subtilis 168 to obtain the recombinant Bacillus subtilis MtDH-Bs168 capable of over-expressing the MtDH gene.
Wherein the pMA5 plasmid was purchased from Biofeng Biofeng; bacillus subtilis 168 was purchased from zemer flies.
Recombinant ligation of gene GlyDH and pMA5 vector, transformation to E.coli.BL21, preparation of related culture medium, etc. was performed according to the method of the third edition of molecular cloning protocols (Huang Petang et al, China, science publishers, 2002); the primers required were all synthesized by Suzhou Jinweizhi Biotechnology, Inc.
Example 11 expression of MtDH-BL21 recombinant Bacillus subtilis
The recombinant Bacillus subtilis MtDH-Bs168 constructed in example 10 was cultured in LB medium, then inoculated into 200mL of liquid LB medium at an inoculum size of 1%, and cultured at 37 ℃ and 200rpm for 24 hours to obtain wet cells of recombinant Bacillus subtilis.
Example 12 regeneration of intracellular NAD with 7-trifluoromethyl-1, 10-ethylideneisoalloxazine chloride salt+The catalyst and the recombinant bacillus subtilis MtDH-Bs168 are coupled to catalyze mannitol to prepare mannose
Mannitol initial concentration 50mM, NAD in 10mL100mM pH9.5 potassium phosphate buffer+The concentration was 0.5mM, the concentration of 7-trifluoromethyl-1, 10-ethylene-based isoalloxazine was 0.1mM, the wet weight concentration of the recombinant Bacillus subtilis MtDH-Bs168 obtained in example 11 was 10g/L, and the reaction solution was communicated with the outside air. The reaction was carried out at 25 ℃ and 150rpm for 12 hours, and the amount of mannose in the reaction system was measured to be 42mM after the completion of the reaction. The recombinant bacillus subtilis and the 7-trifluoromethyl-1, 10-ethylene isoalloxazine are repeatedly used for 5 times in a fed-batch mode, a substrate and a product are removed after each reaction is finished, and the mannose yield is 71% after the recombinant bacillus subtilis and the 7-trifluoromethyl-1, 10-ethylene isoalloxazine are repeatedly used for 5 times.
Example 13 regeneration of intracellular NAD with 7-trifluoromethyl-1, 10-ethylideneisoalloxazine chloride salt+The catalyst is coupled with clostridium acetobutylicum to prepare ethanol, butanol and acetoin
The acetone butanol clostridium (C.acetobutylium)428 is statically cultured to a logarithmic phase at 37 ℃ by using a P2 culture medium, 7-trifluoromethyl-1, 10-ethylene base isoalloxazine is added into a culture solution of the logarithmic phase (the concentration of the 7-trifluoromethyl-1, 10-ethylene base isoalloxazine is 0.5mM), and the mixture is statically and anaerobically fermented for 72 hours at 37 ℃, so that the final ethanol yield is 1g/L, the butanol yield is 12.3g/L, and the acetoin yield is 0.8 g/L.
Wherein, the P2 fermentation medium is divided into four parts which are respectively configured:
1. glucose 60 g/L;
2. 2.2g/L of ammonium acetate, 0.5g/L of monopotassium phosphate and 0.5g/L of dipotassium phosphate;
3. 0.01g/L of sodium chloride, 0.01g/L of manganese sulfate monohydrate, 0.01g/L of ferrous sulfate heptahydrate and 0.2g/L of magnesium sulfate heptahydrate;
4. biotin 0.01mg/L, vitamin B11 mg/L, p-aminobenzoic acid 1 mg/L.
Wherein the concentration of each component is the final concentration of the component in the P2 fermentation medium.
Separately sterilizing solution 1 and solution 2 at 121 deg.C under high pressure steam for 15min, separately dissolving solution 3 and solution 4 in sterile ultrapure water, and filtering with 0.22 μm water system sterile filter membrane. Directly mixing the separately sterilized solution 1 and solution 2 based on 1L fermentation medium as a fermentation system, and adding 50 μ L each of sterilized solution 3 and sterilized solution 4 into the mixed solution 1 and solution 2.
And (2) repeatedly using clostridium acetobutylicum and 7-trifluoromethyl-1, 10-ethylene isoalloxazine for 5 times in a fed-batch mode, removing a substrate and a product after each reaction is finished, and finally obtaining 1.3g/L of ethanol, 12.5g/L of butanol and 0.76g/L of acetoin after 5 times of repeated use.
Example 14 regeneration of intracellular NAD with 7-trifluoromethyl-1, 10-ethylideneisoalloxazine chloride salt+The catalyst is coupled with yeast to prepare the ethanol
Yeast (Saccharomyces) BY4741 is aerobically cultured in a composite culture medium at 30 ℃ and 200rpm until the logarithmic phase, then 7-trifluoromethyl-1, 10-ethylene base isoalloxazine is added into the culture solution at the logarithmic phase (-the concentration of the trifluoromethyl-1, 10-ethylene base isoalloxazine is 0.5mM), aerobically fermented at 32 ℃ and 200rpm for 30h, and the final ethanol yield is 11.6 g/L.
The compound culture medium comprises the following components: 10g/L peptone, 5g/L yeast powder, 90g/L glucose and 9g/L NaCl.
The yeast and the 7-trifluoromethyl-1, 10-ethylene isoalloxazine are repeatedly used for 5 times in a fed-batch mode, substrates and products are removed after each reaction is finished, and after the yeast and the 7-trifluoromethyl-1, 10-ethylene isoalloxazine are repeatedly used for 5 times, the final ethanol yield is 12 g/L.
Comparative example 1 7-trifluoromethyl-1, 10-ethylideneisoalloxazine chloride salt as regenerated NAD+The catalyst and mannitol dehydrogenase are coupled to catalyze mannitol to prepare mannose
In contrast to example 4, the in vitro reaction was carried out in 10mL of 100mM potassium phosphate buffer pH9.5, with an initial concentration of 250mM mannitol, NAD+The concentration is 1mM, the concentration of 7-trifluoromethyl-1, 10-ethylene isoalloxazine is 0.5mM, the dosage of mannitol dehydrogenase is 10 MuM, and the reaction liquid is communicated with the outside air. The reaction was carried out at 25 ℃ and 150rpm for 24 hours, and the amount of mannose in the reaction system was measured to be 100mM after the completion of the reaction. The yield of mannose is significantly lower than that of example 4, and the reaction system cannot be reused.
Wherein the concentration of the mannitol dehydrogenase is equal to the concentration of the mannitol dehydrogenase obtained after 10g/L wet cell disruption and purification of the recombinant Escherichia coli.
Comparative example 2 use of 7-trifluoromethyl-1, 10-ethylideneisoalloxazine chloride salt as regenerated NAD+The catalyst and glycerol dehydrogenase are coupled to catalyze glycerol to prepare dihydroxyacetone DHA
In contrast to example 9, the initial concentration of glycerol was 10g/L, NAD in 10mL of 100mM Tris-HCl buffer pH9.5 under in vitro conditions+The concentration is 10mM, the concentration of 7-trifluoromethyl-1, 10-ethylene isoalloxazine is 0.2mM, glycerol dehydrogenase is 7 mu M, and the reaction liquid is communicated with the outside air. Reacting at 30 ℃ and 150rpm for 2 hours, and measuring the concentration of DHA in the reaction system to be 2.51g/L after the reaction is finished. The DHA yield is significantly lower than that of example 9, and the reaction system cannot be reused.
Wherein the concentration of the glycerol dehydrogenase is equal to the concentration of the glycerol dehydrogenase obtained after 10g/L of recombinant Escherichia coli wet cell disruption and purification.
Comparative example 3 regeneration of intracellular NAD with 7-trifluoromethyl-1, 10-ethylideneisoalloxazine chloride salt+The catalyst and mannitol dehydrogenase are coupled to catalyze mannitol to prepare mannose
In contrast to example 12, in 10mL of 100mM potassium phosphate buffer pH9.5 under in vitro conditions,mannitol initial concentration 50mM, NAD+The concentration is 0.5mM, the concentration of 7-trifluoromethyl-1, 10-ethylene isoalloxazine is 0.1mM, and the mannitol dehydrogenase is 6 mu M, and the reaction liquid is communicated with the outside air. The reaction was carried out at 25 ℃ and 150rpm for 12 hours, and the amount of mannose in the reaction system was measured to be 38mM after the completion of the reaction. The yield of mannose was significantly lower than that of example 12, and the reaction system could not be reused.
Wherein the concentration of the mannitol dehydrogenase is equal to the concentration of the mannitol dehydrogenase obtained after 10g/L wet cell disruption and purification of the recombinant Escherichia coli.
Comparative example 4 use of 7-trifluoromethyl-1, 10-ethylideneisoalloxazine chloride salt as regenerated NAD+The catalyst and mannitol dehydrogenase recombinant escherichia coli before codon optimization are coupled to catalyze mannitol to prepare mannose
The construction and expression methods of recombinant E.coli were the same as in examples 1, 2 and 3, except that the mannitol dehydrogenase gene MtDH was MtDH _ Ag before codon optimization.
Comparison with example 4, in 10mL of 100mM potassium phosphate buffer pH9.5, with an initial concentration of 250mM mannitol, NAD+The concentration is 1mM, the concentration of 7-trifluoromethyl-1, 10-ethylene base isoalloxazine is 0.5mM, the wet weight concentration of the recombinant escherichia coli obtained in comparative example 4 is 10g/L, and the reaction liquid is communicated with the outside air. The reaction was carried out at 25 ℃ and 150rpm for 24 hours, and the amount of mannose in the reaction system was 83mM as measured after the completion of the reaction. The mannose yield is obviously lower than that of example 4, which shows that the mannitol dehydrogenase recombinant Escherichia coli substrate tolerance before codon optimization is low.
Sequence listing
<110> Nanjing university of industry
<120> an oxidation method using whole cells as a catalyst
<160> 2
<170> SIPOSequenceListing 1.0
<210> 1
<211> 1092
<212> DNA
<213> Artificial Sequence (Artificial Sequence)
<400> 1
gcaaaaagca gcgagatcga gcatccggtt aaagcctttg gctgggcagc acgtgatacc 60
acaggcctgc tgagtccgtt caaattcagt cgccgtgcca ccggcgaaaa ggacgttcgc 120
ctgaaggtgc tgttttgcgg cgtttgccat agcgatcacc acatgatcca caacaactgg 180
ggctttacca cctacccgat tgtgccgggt catgagatcg ttggtgtggt taccgaggtt 240
ggtagcaagg tggagaaagt gaaggtgggt gacaacgtgg gcattggctg cctggtgggt 300
agctgccgta gctgcgagag ctgctgcgat aatcgcgaga gtcactgcga gaataccatc 360
gatacctacg gtagcattta cttcgacggc accatgaccc atggtggtta tagcgacacc 420
atggtggcag acgagcattt cattctgcgc tggccgaaaa acctgccgct ggatagcggt 480
gcccctctgc tgtgtgccgg tatcaccacc tatagcccgc tgaagtacta cggcctggac 540
aaacctggca ccaaaatcgg tgtggtgggc ttaggcggtc tgggtcatgt ggccgtgaaa 600
atggccaaag cattcggcgc ccaggttacc gtgattgaca ttagcgaaag caaacgcaaa 660
gaggccctgg aaaaactggg tgcagacagc tttctgctga acagcgatca ggagcagatg 720
aaaggtgccc gtagtagcct ggatggcatc attgacaccg tgccggtgaa tcatcctctg 780
gccccgctgt tcgatctgct gaaaccgaac ggcaaactgg tgatggtggg tgcaccggaa 840
aagccgttcg aactgccggt gtttagcctg ctgaagggcc gtaagctgct gggcggtacc 900
atcaatggcg gcatcaaaga aacccaggag atgctggact ttgccgccaa acacaacatt 960
accgccgacg tggaagtgat cccgatggac tacgttaaca ccgccatgga gcgcctggtg 1020
aaaagcgatg tgcgttaccg cttcgtgatc gatatcgcca acacaatgcg caccgaagaa 1080
<210> 2
<211> 364
<212> PRT
<213> Artificial Sequence (Artificial Sequence)
<400> 2
Ala Lys Ser Ser Glu Ile Glu His Pro Val Lys Ala Phe Gly Trp Ala
1 5 10 15
Ala Arg Asp Thr Thr Gly Leu Leu Ser Pro Phe Lys Phe Ser Arg Arg
20 25 30
Ala Thr Gly Glu Lys Asp Val Arg Leu Lys Val Leu Phe Cys Gly Val
35 40 45
Cys His Ser Asp His His Met Ile His Asn Asn Trp Gly Phe Thr Thr
50 55 60
Tyr Pro Ile Val Pro Gly His Glu Ile Val Gly Val Val Thr Glu Val
65 70 75 80
Gly Ser Lys Val Glu Lys Val Lys Val Gly Asp Asn Val Gly Ile Gly
85 90 95
Cys Leu Val Gly Ser Cys Arg Ser Cys Glu Ser Cys Cys Asp Asn Arg
100 105 110
Glu Ser His Cys Glu Asn Thr Ile Asp Thr Tyr Gly Ser Ile Tyr Phe
115 120 125
Asp Gly Thr Met Thr His Gly Gly Tyr Ser Asp Thr Met Val Ala Asp
130 135 140
Glu His Phe Ile Leu Arg Trp Pro Lys Asn Leu Pro Leu Asp Ser Gly
145 150 155 160
Ala Pro Leu Leu Cys Ala Gly Ile Thr Thr Tyr Ser Pro Leu Lys Tyr
165 170 175
Tyr Gly Leu Asp Lys Pro Gly Thr Lys Ile Gly Val Val Gly Leu Gly
180 185 190
Gly Leu Gly His Val Ala Val Lys Met Ala Lys Ala Phe Gly Ala Gln
195 200 205
Val Thr Val Ile Asp Ile Ser Glu Ser Lys Arg Lys Glu Ala Leu Glu
210 215 220
Lys Leu Gly Ala Asp Ser Phe Leu Leu Asn Ser Asp Gln Glu Gln Met
225 230 235 240
Lys Gly Ala Arg Ser Ser Leu Asp Gly Ile Ile Asp Thr Val Pro Val
245 250 255
Asn His Pro Leu Ala Pro Leu Phe Asp Leu Leu Lys Pro Asn Gly Lys
260 265 270
Leu Val Met Val Gly Ala Pro Glu Lys Pro Phe Glu Leu Pro Val Phe
275 280 285
Ser Leu Leu Lys Gly Arg Lys Leu Leu Gly Gly Thr Ile Asn Gly Gly
290 295 300
Ile Lys Glu Thr Gln Glu Met Leu Asp Phe Ala Ala Lys His Asn Ile
305 310 315 320
Thr Ala Asp Val Glu Val Ile Pro Met Asp Tyr Val Asn Thr Ala Met
325 330 335
Glu Arg Leu Val Lys Ser Asp Val Arg Tyr Arg Phe Val Ile Asp Ile
340 345 350
Ala Asn Thr Met Arg Thr Glu Glu Ser Leu Gly Ala
355 360
Claims (11)
1. An oxidation method using whole cells as a catalyst, characterized in that bridged flavin is used as intracellular NAD (P)+Regenerated catalyst, and intracellular NAD (P) -dependent+Coupled to the redox-enzyme-catalyzed oxidation reaction of (a) to form intracellular NAD (P)+Regenerating the circulating system;
the catalytic system comprises whole cells, depends on NAD (P)+The oxidoreductase substrate, bridged flavin and buffer solution, and the catalytic system also comprises externally added NAD (P)+Said exogenously added NAD (P)+Is 0.05-5 mM; the catalytic system is dependent on NAD (P)+The substrate of the oxidoreductase is subjected to oxidation reaction, after the oxidation reaction is finished, solid-liquid separation is carried out on a catalytic system, and NAD (P) -dependent precipitates are supplemented into the obtained precipitates+The substrate and the buffer solution of the oxidoreductase are used for oxidation reaction, and the whole cells and the bridged flavin are reused for 3-8 times; or the catalytic system comprises whole cells, bridged flavin, and cell culture fluid, wherein the cell culture fluid comprises NAD (P) -dependent+The catalytic system catalyzes the dependence on NAD (P)+Carrying out oxidation reaction on a substrate of the oxidoreductase, carrying out solid-liquid separation on a catalytic system after the oxidation reaction is finished, supplementing a cell culture solution into the obtained precipitate, and continuing the oxidation reaction, wherein the whole cells and bridged flavin are repeatedly used for 3-8 times;
the bridged flavin has the following structural general formula:
wherein R is1And R2Independently of one another, from: hydrogen, methyl, trifluoromethyl, methoxy, halogen atom, nitro and amino; r3Selected from: hydrogen, C1-C5 alkyl, phenyl and benzyl; x-Selected from: halide ion, nitrate radical, triflate ion.
2. An oxidation process according to claim 1, wherein the whole cells are selected from Escherichia coli (Escherichia coli) cells, yeast (saccharomyces) cells, Clostridium acetobutylicum (Clostridium acetobutylicum) cells, Corynebacterium glutamicum (Corynebacterium glutamicum) cells, Bacillus subtilis (Bacillus subtilis) cells, streptomyces (streptomycetetaceae) cells, Aspergillus niger (Aspergillus niger) cells, or recombinant cells of the above cells.
3. The oxidation process according to claim 2, wherein the whole cells are cells cultured to a log phase, a stationary phase or a decline phase.
4. An oxidation process according to claim 2, wherein the whole cells are E.coli (Escherichia coli) cells or recombinant E.coli cells.
5. The oxidation process according to claim 2, wherein the recombinant cell is a recombinant cell obtained by knocking out a cellular gene, expressing an endogenous gene or expressing an exogenous gene.
6. The oxidation process of claim 1, wherein the concentration of whole cells in the catalytic system is from 0.01 to 100 g/L.
7. An oxidation process according to claim 1, wherein the bridged flavin is 7-trifluoromethyl-1, 10-ethylideneisoalloxazine chloride, 8-chloro-1, 10-ethylideneisoalloxazine chloride or 1, 10-ethylideneisoalloxazine chloride.
8. An oxidation process according to claim 1, wherein the bridged flavins are present in the catalytic system in a concentration of 0.001-10 mM.
9. The oxidation process of claim 1, wherein the NAD (P) -dependent oxidation is carried out+The oxidoreductase of (a) is selected from all enzymes of EC1.1.1.X, EC1.2.1.X, EC1.3.1.X, EC1.4.1.X, EC1.5.1.X, EC1.6.1.X, EC1.7.1.X, EC1.8.1.X, EC1.10.1.X, EC1.12.1.X, EC1.13.1.X, EC1.16.1.X, EC1.17.1.X, EC1.18.1.X, EC1.20.1.X, and EC1.22.1. X.
10. The oxidation process of claim 9, wherein the NAD (P) -dependent oxidation is carried out+The oxidoreductase of (2) is mannitol dehydrogenase, glycerol dehydrogenase, alcohol dehydrogenase, or acetyl-CoA dehydrogenase.
11. An oxidation process according to claim 1, wherein the catalytic system is NAD (P) -dependent+The initial concentration of substrate for the oxidoreductase of (3) is 50-1000 mM.
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN201810755903.9A CN108823258B (en) | 2018-07-11 | 2018-07-11 | Oxidation method using whole cells as catalyst |
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN201810755903.9A CN108823258B (en) | 2018-07-11 | 2018-07-11 | Oxidation method using whole cells as catalyst |
Publications (2)
Publication Number | Publication Date |
---|---|
CN108823258A CN108823258A (en) | 2018-11-16 |
CN108823258B true CN108823258B (en) | 2022-02-11 |
Family
ID=64135776
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CN201810755903.9A Active CN108823258B (en) | 2018-07-11 | 2018-07-11 | Oxidation method using whole cells as catalyst |
Country Status (1)
Country | Link |
---|---|
CN (1) | CN108823258B (en) |
Families Citing this family (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN111826409A (en) * | 2019-04-16 | 2020-10-27 | 中国科学院大连化学物理研究所 | Method for reducing NAD analogue by using methanol |
CN112375040B (en) * | 2020-11-27 | 2022-03-04 | 南京工业大学 | Method for preparing nitrogen-containing heterocyclic compound and derivative thereof by enzyme-chemical cascade method |
Citations (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN105622693A (en) * | 2016-01-08 | 2016-06-01 | 南京工业大学 | Oxidized coenzyme NAD (P)+Chemical regeneration method of |
CN106811488A (en) * | 2015-12-02 | 2017-06-09 | 中国科学院大连化学物理研究所 | A kind of bioanalysis coproduction mannitol and gluconic acid or the method for gluconate |
-
2018
- 2018-07-11 CN CN201810755903.9A patent/CN108823258B/en active Active
Patent Citations (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN106811488A (en) * | 2015-12-02 | 2017-06-09 | 中国科学院大连化学物理研究所 | A kind of bioanalysis coproduction mannitol and gluconic acid or the method for gluconate |
CN105622693A (en) * | 2016-01-08 | 2016-06-01 | 南京工业大学 | Oxidized coenzyme NAD (P)+Chemical regeneration method of |
Also Published As
Publication number | Publication date |
---|---|
CN108823258A (en) | 2018-11-16 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
JP6898365B2 (en) | Recombinant microorganisms and how to use them | |
Berrıos-Rivera et al. | Metabolic engineering of Escherichia coli: increase of NADH availability by overexpressing an NAD+-dependent formate dehydrogenase | |
KR102321136B1 (en) | genetically engineered bacteria | |
Berrı́os-Rivera et al. | The effect of NAPRTase overexpression on the total levels of NAD, the NADH/NAD+ ratio, and the distribution of metabolites in Escherichia coli | |
US5032514A (en) | Metabolic pathway engineering to increase production of ascorbic acid intermediates | |
CN109750009B (en) | Glufosinate-ammonium dehydrogenase mutant and application thereof | |
JP5627546B2 (en) | Method for enantioselective enzymatic reduction of secodione derivatives | |
CN110373370B (en) | Catalytic system coupled with ATP regeneration system and application of catalytic system in glutathione production process | |
KR20010093149A (en) | Method for producing ascorbic acid intermediates | |
CN108823258B (en) | Oxidation method using whole cells as catalyst | |
CN114350727B (en) | Method for synthesizing D-psicose by combining phosphorylation and ATP regeneration system | |
AU2018213395A1 (en) | Molecular switches | |
JP5496356B2 (en) | Xylitol producing strain introduced with arabinose metabolic pathway and xylitol producing method using the same | |
EP1097216B1 (en) | Metabolically engineered microbial cell with an altered metabolite production | |
CN113583988A (en) | Amino acid dehydrogenase mutant and application thereof | |
US8741652B2 (en) | Genetically transformed microorganisms with simultaneous enhancement of reduction potential and reductive enzyme activities for biomass fermentation | |
WO2013061571A1 (en) | Method for producing isobutanol and recombinant microorganism capable of producing isobutanol | |
Miyaji | Methanol Biosynthesis from Methane Using Methylosinus trichosporium OB3b Grown in Medium Containing High Copper Concentration | |
CN114717250B (en) | Method for improving cordycepin yield by modifying cordycepin based on cofactor metabolic engineering strategy and application | |
CN110628849A (en) | Method for regenerating oxidation state nicotinamide cofactor | |
CN114410494B (en) | Saccharomyces cerevisiae engineering bacteria for producing rosmarinic acid and construction method and application thereof | |
EP3960869A1 (en) | Production method for l-cyclic amino acids | |
CN114752574B (en) | Enzyme catalysis system, catalase, preparation method and application | |
CN117925744B (en) | Use of non-ribosomal peptide synthetases in the production of decarboxylated carnosine | |
CN110628835B (en) | Method for preparing xylitol by utilizing pH self-balancing catalytic system |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
PB01 | Publication | ||
PB01 | Publication | ||
SE01 | Entry into force of request for substantive examination | ||
SE01 | Entry into force of request for substantive examination | ||
GR01 | Patent grant | ||
GR01 | Patent grant |